GSK is making its largest acquisition in more than a decade, and Montgomery County has a clear stake in what comes next, writes John George for The Philadelphia Business Journal.
The London-based pharmaceutical giant, which has major research and manufacturing operations in Upper Providence and Upper Merion, has agreed to acquire Boston-based Nuvalent for $10.6 billion.
The deal is designed to strengthen GSK’s oncology pipeline, particularly in lung cancer. Nuvalent has two late-stage drug candidates aimed at non-small cell lung cancer.
GSK plans to buy all outstanding Nuvalent shares for $124 per share in cash. The price represented a roughly 40% premium to Nuvalent’s June 8 closing price.
The acquisition is expected to close in the third quarter.
What Nuvalent Brings to the Table
For GSK, the deal is about accelerating its push into cancer therapies. Nuvalent’s experimental treatments, zidesamtinib and neladalkib, could launch later this year if approved by the Food and Drug Administration.
GSK also has its own experimental lung cancer drug, Ris-Rez, in Phase 3 clinical development, giving the company a broader platform in a lucrative and highly competitive part of the pharmaceutical industry.
The deal is expected to add to GSK’s sales and operating profit in 2027 and to core earnings per share by 2029.
A New CEO’s First Big Move
The acquisition is also one of the first major strategic moves under Luke Miels, who became GSK’s CEO on January 1.
It follows the company’s $2.2 billion acquisition of Rapt Therapeutics earlier this year. The deal focused on a food allergy antibody aimed at strengthening GSK’s respiratory and immunology pipeline.
What It Means for Montgomery County
Locally, the Nuvalent deal lands as GSK is already deepening its investment in the Philadelphia region.
The company has about 4,000 employees in the area, including administrative offices in University City and major Montgomery County sites in Upper Providence and Upper Merion.
GSK has also announced plans for a new manufacturing facility in Upper Merion. The plan is part of a broader $30 billion U.S. investment in research and supply chain infrastructure.
That makes the latest deal more than a Wall Street transaction.
For Montgomery County, it reinforces GSK’s role as one of the region’s most important life-sciences anchors. Local operations tied directly to the company’s next generation of cancer, respiratory, immunology, and specialty medicines.
Learn more about GSK’s new major acquisition and what it means for its Montgomery County presence in The Philadelphia Business Journal.
